EN
/
SE

Press Releases

  • All
  • Staff change
  • Regulatory
  • PR
  • Other Corporate Information
  • Other
  • News
  • mfn-cus-regulatory
  • mfn-cus-disclaimer
  • Listing Regulation
  • IR
  • Executive staff changes
  • English
  • Corporate Information
  • Corporate Action
  • 2024
  • 2023
  • 2022
  • 2021

Occlutech Q3 2024 Performance Update: Strong Growth & Increased Efficiency

November 15, 2024
Read More

Occlutech® Announces Commercial Cases of Occlutech ASD Occluder Device Implantation in the U.S.

August 28, 2024
Read More

Occlutech Q2 Update: Strong Growth, Efficiency, and Strategic Execution

August 15, 2024
Read More

Occlutech Q1 2024 – Performance Update: A Strong Start to the Year

May 28, 2024
Read More

Occlutech Q4 2023 – key approval in the US, solid progress in clinical study and continued strong growth

March 5, 2024
Read More

Occlutech® Announces FDA Approval of its Occlutech® ASD Occluder and Occlutech® Pistol Pusher, a Minimally Invasive Cardiac Device and Delivery System to Treat Atrial Septal Defects

January 8, 2024
Read More

Occlutech Q3 2023 – Achieving continued growth across geographies and sales channels with a positive outlook for year end

December 6, 2023
Read More

Occlutech Q2 2023 – Continued strong revenue growth

September 5, 2023
Read More

Occlutech Q1 2023 – Growth momentum with increased sales and marketing activities

May 26, 2023
Read More

Occlutech Year-end report 2022 – Significant uptick in sales growth as transformation processes are reaching an end

May 3, 2023
Read More
Load More Press Releases
Subscribe

Please select a site

International
The United States